Corona Remedies IPO worth ₹655.37 Cr will open for subscription from 8 Dec to 10 Dec 2025. Corona Remedies allotment is expected on 11 Dec and shares are likely to be listed on BSE & NSE on 15 Dec. Price band for the IPO is set between ₹1008 to ₹1062 per share and Corona Remedies GMP today stands at 34%.
Corona Remedies IPO GMP Live Rates Day by Day
Corona Remedies IPO GMP today (5th Dec 2025) stands at 34%. GMP values change daily and we’ll keep you updated with the latest figures.
Remember, Grey Market Premium is an unofficial price at which an IPO trades before listing, offering an early hint of its performance. A positive GMP indicates potential gains, while a negative GMP signals a discount. Since GMP is highly volatile, investors should not rely on it alone and must consider other factors before investing in Corona Remedies IPO.
GMP figures are for news purposes only. We neither trade nor recommend trading in the grey market.
| GMP Date | IPO Price | GMP | Estimated Listing Price | Estimated Profit |
|---|---|---|---|---|
| 12-12-2025 | ₹ 1,062 | ₹ 291 | ₹1353 (27.40%) | ₹ 4,074 |
| 11-12-2025 | ₹ 1,062 | ₹ 291 | ₹1353 (27.40%) | ₹ 4,074 |
| 10-12-2025 | ₹ 1,062 | ₹ 295 | ₹1357 (27.78%) | ₹ 4,130 |
| 09-12-2025 | ₹ 1,062 | ₹ 270 | ₹1332 (25.42%) | ₹ 3,780 |
| 08-12-2025 | ₹ 1,062 | ₹ 262 | ₹1324 (24.67%) | ₹ 3,668 |
| 05-12-2025 | ₹ 1,062 | ₹ 365 | ₹1427 (34.37%) | ₹ 5,110 |
Corona Remedies IPO Details
- Corona Remedies’s IPO is worth ₹655.37 Cr, which is entirely an offer for sale.
- Corona Remedies’s will open for subscription on 8 Dec 2025 and close on 10 Dec 2025. And the price band is set between ₹1008- ₹1062.
- Corona Remedies’s allotment is likely to take place on 11 Dec 2025 and the shares are expected to be listed on BSE and NSE on 15 Dec 2025.
- The promoters currently hold 72.50%, which will come down after the IPO listing.
- Bigshare Services will be the registrar for Corona Remedies's.
Corona Remedies IPO Dates
Here are some important dates for the upcoming IPO of Corona Remedies.
| IPO Open Date | 08-Dec-25 |
| IPO Close Date | 10-Dec-25 |
| IPO Allotment Date | 11-Dec-25 |
| Initiation of Refunds | 12-Nov-25 |
| Demat Credits | 12-Nov-25 |
| Listing Date | 15-Nov-25 |
| Listing on | BSE, NSE |
Corona Remedies IPO Reservation
For Corona Remedies IPO, 35% has been reserved for retail investors.
| Investor Category | Shares Offered |
|---|---|
| QIB Investors | 50% |
| Retail Investors | 35% |
| NII (HNI) Investors | 15% |
Corona Remedies IPO Lot Size
Retail investors can apply for a minimum of 1 lot, which includes 14 shares costing ₹14,868. Maximum investment allowed for retail investors is 13 lots, which totals 182 shares and costs ₹1,93,284.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 14 | ₹ 14,868 |
| Retail (Max) | 13 | 182 | ₹ 1,93,284 |
| S-HNI (Min) | 14 | 196 | ₹ 2,08,152 |
| S-HNI (Max) | 67 | 938 | ₹ 9,96,156 |
| B-HNI (Min) | 68 | 952 | ₹ 10,11,024 |
About Corona Remedies IPO
Corona Remedies, founded in 2004, is a pharmaceutical company focused on developing and marketing medicines across therapeutic areas such as women’s healthcare, cardio-diabetes, pain management, urology, and general wellness.
As of June 30, 2025, the company offers 71 brands across these segments and has built a strong presence in the Indian pharmaceutical market through a wide marketing network of 2,671 medical representatives operating across 22 states. This helps the company maintain strong connections with doctors and hospitals and ensures deep market penetration.
Corona Remedies runs two manufacturing facilities in Gujarat, with a total installed capacity of 1,285 million units per year, enabling large-scale production of tablets, capsules, and other formulations.
The company continues to expand through new product launches and strategic acquisitions, strengthening its portfolio and enhancing its reach within India’s growing healthcare sector.
Corona Remedies Financial Performance
Corona Remedies reported PAT of ₹149.43 Cr on 31 March 2025 and in FY24 reported ₹90.50 Cr. Over the past 3 years, the company’s PAT has been continuously growing. All financial details are provided in the table below.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets (₹Cr) | 929.86 | 830.58 | 595.02 |
| Total income (₹Cr) | 1,202.35 | 1,020.93 | 891.1 |
| PAT (₹Cr) | 149.43 | 90.5 | 84.93 |
| EBITDA (₹Cr) | 245.91 | 161.19 | 135.03 |
| Net Worth (₹Cr) | 606.34 | 480.41 | 408.52 |
| Reserves and Surplus (₹Cr) | 545.18 | 419.25 | 347.36 |
| Total Borrowing (₹Cr) | 62.7 | 134.14 | 2.33 |
| PAT Margin (%) | 12.49% | 8.92% | 9.61% |
| ROE (%) | 27.50% | 20.36% | 23.29% |
| ROCE (%) | 41.32% | 31.19% | 28.36% |
| Debt/Equity | 0.1 | 0.28 | 0.01 |
Corona Remedies IPO Peer Comparison from RHP
Corona Remedies has the lowest EPS but a decent P/E compared to its peers. Higher EPS is always considered better. Below is a quick comparison of Corona Remedies vs Abbott India vs Pfizer
| Company | EPS Diluted (₹) | P/E (x) |
|---|---|---|
| Corona Remidies | 24.43 | 43.17 |
| Abbott India | 665.62 | 45.17 |
| Alkem Laboratories | 181.11 | 31.39 |
| Eris Lifesciences | 25.81 | 61.81 |
| Glaxosmithkline Pharmaceuticals | 54.76 | 46.87 |
| J.b.chemicals & Pharmaceuticals | 41.56 | 42.6 |
| Mankind Pharma | 49.2 | 45.77 |
| Pfizer | 167.79 | 29.63 |
| Sanofi India | 179.46 | 24.47 |
| Torrent Pharmaceuticals | 56.47 | 65.91 |
Corona Remedies Strengths and Weaknesses
Knowing about the strengths and weaknesses of Corona Remedies helps you make an informed decision.
- The company has shown strong revenue growth, recording about 21% CAGR over the past three years.
- It offers a wide product range across multiple therapeutic areas, reducing reliance on any single segment.
- A strong distribution network helps the company reach both urban and semi-urban markets effectively.
- Corona Remedies holds leading positions in key areas like women’s health and pain management.
- The business needs high working capital, with an operating cycle of over 150 days, which can strain liquidity.
- Being in the pharmaceutical industry, the company faces regulatory risks, including pricing controls and compliance requirements.
- It depends on contract manufacturing for some products, which may affect control over quality and timelines.
- Domestic pharma market is competitive and price-sensitive, which may impact margins.
Corona Remedies GMP FAQs
What is Corona Remedies GMP Today?
Corona Remedies GMP today is ₹365
What are Corona Remedies Expected Returns?
Corona Remedies Expected Returns are 34%, as of 5th Dec, this may change in the coming days.
When will Corona Remedies open and close?
Corona Remedies’s will open for subscription on 8 Dec 2025 and close on 10 Dec 2025.
What is the lot size for Corona Remedies?
Retail Investors can bid for a minimum of 1 lot, which includes 14 shares. And one lot will cost you ₹14,868.
What is the share allotment date for Corona Remedies?
The allotment of shares is expected to be completed by 11 Dec 2025.
Who is the registrar of Corona Remedies?
Bigshare Services is the registrar for Corona Remedies’s.
Is Corona Remedies good to buy?
Corona Remedies may attract investors due to its growing PAT and strong ROE & ROCE.
Happy investing and thank you for reading!
Disclaimer:
This website content is only for educational purposes, not investment advice. Before making any investment, it’s important to do your own research and be fully informed. Investing in the stock market includes risks, and you should carefully read the Risk Disclosure documents before proceeding. Please remember that past performance doesn’t guarantee future results, and due to market fluctuations, your investment goals may not always be achieved.
